The mir|detect GmbH has signed an exclusive distribution agreement with EDX Medical Group PLC concluded. The agreement covers the distribution of the CE-IVD-certified M371-Tests for Great Britain, Sweden, Finland, Norway and Denmark.
EDX Medical Group, based in Cambridge (UK), develops diagnostic products and digital solutions to support precision medicine in cancer, cardiovascular and infectious diseases. The partnership will enable the M371-Test was launched for the first time in several key markets in Northern Europe to improve access to modern molecular diagnostics for testicular cancer.
The M371-Test is a Minimally invasive blood testwho is the Early detection and follow-up of testicular germ cell tumours (TGCTs) the most common form of cancer in young men. Compared to conventional serum tumour markers, the test offers significantly higher sensitivity and specificity. Studies show a Sensitivity of over 90 % and a Specificity of 100 %which makes it one of the most reliable diagnostic solutions for testicular cancer.
"In EDX Medical, we have found an experienced partner who shares our vision of making molecular diagnostics more widely available," says Dr Nina WinterCEO at mir|detect. "Together we can establish the M371-Test in clinics and laboratories in the UK and Northern Europe and thus sustainably improve diagnostics for young men with testicular cancer."
The partnership marks another important milestone in mir|detect's European expansion. Following successful collaborations in Germany, Portugal and Croatia, the company is strengthening its market presence in Northern Europe with EDX Medical and laying the foundations for a broader international roll-out of the test.
Further information can be found in our Sales partner area or under www.edxmedical.co.uk to find.
